Endologix begins trial geared towards US cuff approval:
This article was originally published in Clinica
Endologix, of Irvine, California, has started a multicentre, controlled investigational device exemption (IDE) trial intended to support US FDA approval of the large 34mm diameter Powerlink infrarenal cuff in conjunction with the firm's Powerlink product. Powerlink is a bifurcated endoluminal stent graft (ELG) approved by the FDA for the minimally-invasive treatment of abdominal aortic aneurysm (AAA). It is estimated that 35,000 ELG procedures will be performed in the US this year.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.